BAM
SAGE

Bellevue Asset Management’s Sage Therapeutics SAGE Stock Holding History

Bellevue Asset Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-13
Closed -$1K – 632
2019
Q4 		$1K Buy
+13
New +$1.6K ﹤0.01% 520

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Bellevue Asset Management's SAGE Position: Q1 2020 in Review

Bellevue Asset Management sold out of Sage Therapeutics (SAGE) in Q1 2020, closing a stake of 13 shares — an estimated $1K sold.

Bellevue Asset Management first reported a position in SAGE in Q4 2019 and held it in 1 quarter. The position peaked at $1K in Q4 2019. 229 funds tracked by Wall St. Rank hold SAGE as of Q1 2020.

  • Bellevue Asset Management reported no remaining Sage Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Bellevue Asset Management sold 13 Sage Therapeutics shares in Q1 2020, an estimated $1K.
  • Bellevue Asset Management first reported a position in Sage Therapeutics in Q4 2019 and held it in 1 quarter.
  • Bellevue Asset Management's Sage Therapeutics position peaked at $1K in Q4 2019.
  • 229 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2020.

Based on Bellevue Asset Management's 13F filing for Q1 2020, filed 13 May 2020.